Evidence map›Paper›PMID 25143710›Full record

ArticleDrug design, development and therapy2014

Efficacy of the small molecule inhibitor of Lipid II BAS00127538 against Acinetobacter baumannii.

Erik P H de Leeuw

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug design, development and therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Non-antibiotic prevention and treatment againstFrontiers in microbiology · 2023
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Erik P H de LeeuwInstitute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA.
University of Maryland, Baltimore · US

Funding

Molecular Basis of Human Defensins as Novel Lipid II Binding Peptide AntibioticsR21AI092033 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI DE LEEUW, ERIK · 2011 to 2012
$422k
NIAID NIH HHS R21 AI092033NIAID NIH HHS R21AI092033
6 · The paper itself

Abstract

objectiveTo test the activity of a small molecule compound that targets Lipid II against Acinetobacter baumannii.

methodsSusceptibility to small molecule Lipid II inhibitor BAS00127538 was assessed using carbapenem- and colistin-resistant clinical isolates of A. baumannii. In addition, synergy between colisitin and this compound was assessed.

resultsSmall molecule Lipid II inhibitor BAS00127538 potently acts against A. baumannii and acts synergistically with colistin.

conclusionFor the first time, a compound that targets Lipid II is described that acts against multi-drug resistant isolates of A. baumannii. The synergy with colistin warrants further lead development of BAS00127538.

Indexed as

Acinetobacter baumanniiAnti-Bacterial AgentsCarbapenemsColistinDrug Resistance, Multiple, BacterialDrug SynergismIndolesMicrobial Sensitivity TestsPyransUridine Diphosphate N-Acetylmuramic AcidAnti-Bacterial AgentsBAS00127538CarbapenemsColistinIndolesmuramyl-NAc-(pentapeptide)pyrophosphoryl-undecaprenolPyransUridine Diphosphate N-Acetylmuramic AcidAcinetobacter baumanniidrug developmentLipid II

Identifiers

PMID25143710
PMCPMC4134019
OpenAlexW1990764361

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.